Tirzepatide

Allurion launches AllurionMeds GLP-1 programme, integrating AI-supported monitoring and drug dispensary services to address weight loss challenges, including medication adherence, muscle and bone mass loss, and healthcare costs.

Multiple biotech companies announced significant financing rounds to advance various medical technologies and treatments, including Seaport Therapeutics' $225 million Series B for Glyph platform advancements, Alentis Therapeutics' $181.4 million Series D for ADCs targeting CLDN1, Alpha-9's $175 million Series C for targeted radiopharmaceuticals, Axonis Therapeutics' $115 million Series A for epilepsy and pain treatment, Evommune's $115 million Series C for chronic urticaria and atopic dermatitis, Trace Neuroscience's $101 million Series A for neurodegenerative disease treatments, Kivu Bioscience's $92 million Series A for ADC programs, SynOx's $92 million Series B for TGCT treatment, Agomab Therapeutics' $89 million Series D for Crohn’s disease, TRex Bio's $84 million Series B for atopic dermatitis and ulcerative colitis, Pathos AI's $62 million Series C for AI-powered drug development, ATB Therapeutics' $56.9 million Series A for antibody platform expansion, INBRAIN Neuroelectronics' $50 million Series B for BCI-Tx platform, PrognomiQ's $34 million Series D for lung cancer early detection, Archon Biosciences' $20 million seed funding for computational protein design, Passkey Therapeutics' $20 million seed funding for rare protein combinations, Zucara Therapeutics' $20 million Series B for hypoglycemia prevention, Alimetry's $18 million Series A for gut health monitoring, Sonavex's $15 million Series A for AV fistula maturation assessments, Citizen Health's $14.5 million seed funding for rare disease care, Aralez Bio's $12 million Series A for noncanonical amino acid manufacturing, Ikarovec's $10.3 million seed funding for sight loss therapy, CrossBridge Bio's $10 million seed financing for ADC therapies, Biometry's $5 million seed funding for asthma and COPD care, Ataraxis AI's $4 million seed funding for AI-native cancer diagnostic tests, and Amplified Sciences' $2.6 million seed funding for transformative diagnostics platform.

FDA study links asthma drug Singulair (montelukast) to severe mental health issues and suicide, though more data is needed to understand its impact on the nervous system.

CVS Caremark adjusts diabetes drug coverage for 2025, removing older therapies like V-go Infusion Pump and Merck's Janumet/Janumet XR, in favor of newer products and generics. Notable additions include Twiist infusion system, Zituvimet, and biosimilars to Lantus. CVS also adds HIV, cancer, and mental health treatments to its formulary.

Despite access to obesity drugs like Wegovy, some patients, like Danielle Griffin, find they don't lose weight. Experts estimate 20% of patients may not respond well to these medications due to genetic, hormonal, and brain regulation variability. Alternative treatments and lifestyle changes are suggested for non-responders.

Expert from Baylor College of Medicine offers tips for holiday eating while on GLP-1 medications, emphasizing small portions, nutrient-dense diet, and hydration to maintain weight loss and diabetes control.

GLP-1 weight-loss meds like Ozempic cause increased food waste as appetites falter, but waste declines with medication acclimation. New users report 25% more food waste, with a 30% increase among those using the meds for 90 days or less. Nausea and dietary changes, such as reduced intake of alcohol, pasta, and sweets, contribute to the waste. Long-term users lose an average of 20% of their body weight.